Opinion|Videos|November 16, 2026

Coordinating Care and Comparing TIL and TCR Cell Therapies

Successful cellular therapy depends on careful coordination and on understanding how the major platforms differ.

Successful cellular therapy depends on careful coordination and on understanding how the major platforms differ. In this segment, the panel describes how treating centers partner with referring oncologists through workup, toxicity monitoring, prophylaxis, and follow-up. They also walk through the realistic timeline from consultation to surgical harvest and product manufacturing, a period during which disease may still be progressing. Faculty explain why they taper immunosuppression from prior immune-related toxicity as quickly as possible, since heavy steroid exposure can impair ex vivo T-cell expansion. The discussion then contrasts the two main platforms. Tumor-infiltrating lymphocyte (TIL) therapy is a polyclonal product derived from a surgically resected tumor and given after lymphodepleting chemotherapy with high-dose interleukin support. Engineered T-cell receptor (TCR) therapy is manufactured from peripheral blood collected by leukapheresis and directed at a single target. The panel notes that both approaches can recognize intracellular antigens, unlike chimeric antigen receptor T-cell therapies.


Related to this article